Αποτελέσματα Αναζήτησης
The first table includes patient-level demographic information: Including Actual Arm Description, Age, Sex, Weight, Race & Date/Time of Informed Consent. The next table represents exposure to study-drug dosage information: Cycle/Visit Information, Start/End date of treatment, Dosage, Dosage Units.
26 Μαΐ 2020 · ☑ Recommendations are provided to integrate prior knowledge (prediction), clinical trial experience, and real-world data into a systematic way to create timely drug dosing for patient characteristics likely to influence outcome. WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
21 Μαρ 2017 · In this work, we propose, study, and compare methods to incorporate PK measures in the dose allocation process during a phase I clinical trial. These methods do this in different ways, including using PK observations as a covariate, as the dependent variable or in a hierarchical model.
1 Φεβ 2021 · Commonly, current dose-finding designs involve escalation of more than one agent, identification of an optimal biologic dose or minimum effective dose (MED), on the basis of safety and efficacy, and late-onset toxicities.
25 Σεπ 2021 · The need to identify an appropriate set of doses typically starts before preclinical studies, continues with determining the starting dose and dose range for first-in-human and the dose for proof-of-concept studies.
19 Μαΐ 2021 · Although finding the right dose encompasses a broader theme (i.e., phase I clinical trial design), the scope of this article focuses on alternative mechanisms to potentiate biologic effect, minimize toxicity, and reduce costs through dose modification.
21 Απρ 2020 · These factors can be assessed to determine if a drug should or should not be a precision dosing candidate. Figure 1 outlines key drug, disease state, patient population, and clinical implementation considerations that can be used to guide the assessment of precision dosing candidates.
